Vivus (VVUS) volatility low into positive phase 3 results

Vivus (Nasdaq: VVUS) announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction in patients following a radical prostatectomy. Overall option implied volatility of 56 is below its six-month average of 72 according to Track Data.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Netflix (NFLX) call put ratio 2.2 calls to 1 put into quarter results
• Blackrock Ny Municipal Inc Tr (BNY) call put ratio 1 call to 1.5 puts into quarter results
• Dyne Therapeutics Inc. (DYN) call put ratio 1.1 calls to 1 put as share price down 1.5%